{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:42Z","timestamp":1791216762082,"version":"4.1.0"},"reference-count":51,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15638","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:08:24Z","timestamp":1778044104000},"page":"1-12","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy retreatment with serplulimab vs. chemotherapy in extensive\u2011stage advanced small cell lung cancer"],"prefix":"10.3892","volume":"32","author":[{"given":"Xinhang","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[{"name":"College of Clinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiao","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Ultrasound Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"key20260619091646_b1-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","article-title":"Emerging strategies for the treatment of small cell lung cancer: A review","volume":"9","author":"Petty","year":"2023","journal-title":"JAMA Oncol"},{"key":"key20260619091646_b2-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet"},{"key":"key20260619091646_b3-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"e121S","DOI":"10.1378\/chest.12-2352","article-title":"Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Ost","year":"2013","journal-title":"Chest"},{"key":"key20260619091646_b4-ol-32-1-15638","article-title":"Small Cell Lung Cancer","author":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2022"},{"key":"key20260619091646_b5-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.4081\/oncol.2012.e4","article-title":"Chemotherapy for small cell lung cancer: A comprehensive review","volume":"6","author":"Karim","year":"2012","journal-title":"Oncol Rev"},{"key":"key20260619091646_b6-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N Engl J Med"},{"key":"key20260619091646_b7-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20260619091646_b8-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20260619091646_b9-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1097\/JTO.0b013e3181f2451c","article-title":"Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: Systematic review with meta-analysis","volume":"5","author":"Lima","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20260619091646_b10-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in Extensive-Stage Small-Cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260619091646_b11-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"key20260619091646_b12-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","article-title":"A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer","volume":"7","author":"Owonikoko","year":"2012","journal-title":"J Thorac Oncol"},{"key":"key20260619091646_b13-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O'Brien","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20260619091646_b14-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): A multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"key":"key20260619091646_b15-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejca.2021.07.002","article-title":"The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients","volume":"155","author":"Zaremba","year":"2021","journal-title":"Eur J Cancer"},{"key":"key20260619091646_b16-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: Seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"key20260619091646_b17-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: Mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomark Res"},{"key":"key20260619091646_b18-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20260619091646_b19-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"key20260619091646_b20-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"key20260619091646_b21-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"key20260619091646_b22-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"key20260619091646_b23-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"106047","DOI":"10.1016\/j.bioorg.2022.106047","article-title":"Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1\/PD-L1 complex formation for cancer therapy","volume":"128","author":"Bojko","year":"2022","journal-title":"Bioorg Chem"},{"key":"key20260619091646_b24-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"e250009","DOI":"10.1136\/bcr-2022-250009","article-title":"Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC","volume":"15","author":"Cerniglia","year":"2022","journal-title":"BMJ Case Rep"},{"key":"key20260619091646_b25-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"967559","DOI":"10.3389\/fphar.2022.967559","article-title":"Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"key20260619091646_b26-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41416-022-02043-7","article-title":"Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: An open-label, single-arm, multicentre, phase II trial","volume":"127","author":"Qin","year":"2022","journal-title":"Br J Cancer"},{"key":"key20260619091646_b27-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of First-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"key20260619091646_b28-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1197044","DOI":"10.3389\/fimmu.2023.1197044","article-title":"Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: A Bayesian network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"key20260619091646_b29-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"562315","DOI":"10.3389\/fonc.2021.562315","article-title":"Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and Meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"key20260619091646_b30-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: Recommendations from the first meeting of the SITC immunotherapy resistance taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20260619091646_b31-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20260619091646_b32-ol-32-1-15638","article-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"key20260619091646_b33-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20260619091646_b34-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W","article-title":"The karnofsky performance status scale. An examination of its reliability and validity in a research setting","volume":"53","author":"Mor","year":"1984","journal-title":"Cancer"},{"key":"key20260619091646_b35-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20260619091646_b36-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: First-line and Second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260619091646_b37-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with Extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20260619091646_b38-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jtho.2019.01.008","article-title":"A Randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial","volume":"14","author":"Pujol","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key20260619091646_b39-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key20260619091646_b40-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jama.2022.16442","article-title":"Serplulimab with chemotherapy in Extensive-Stage SCLC","volume":"328","author":"Choudhury","year":"2022","journal-title":"JAMA"},{"key":"key20260619091646_b41-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers13040663","article-title":"Recent advancements in the mechanisms underlying resistance to PD-1\/PD-L1 blockade immunotherapy","volume":"13","author":"Yuan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260619091646_b42-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"key20260619091646_b43-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"key20260619091646_b44-ol-32-1-15638","first-page":"e92","article-title":"Immunotherapy for gastric cancer: Advances and challenges","volume":"3","author":"Zhang","year":"2024","journal-title":"Med Comm Oncol"},{"key":"key20260619091646_b45-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"key20260619091646_b46-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"key20260619091646_b47-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Oncoimmunology"},{"key":"key20260619091646_b48-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"key20260619091646_b49-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.7150\/ijbs.82776","article-title":"Current Status in rechallenge of immunotherapy","volume":"19","author":"Hu","year":"2023","journal-title":"Int J Biol Sci"},{"key":"key20260619091646_b50-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/JTO.0b013e3181b27b15","article-title":"Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): The importance of smoking history, socioeconomic and marital statuses, and ethnicity","volume":"4","author":"Ou","year":"2009","journal-title":"J Thorac Oncol"},{"key":"key20260619091646_b51-ol-32-1-15638","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/pro6.1225","article-title":"Clinical application of high-LET radiotherapy combined with immunotherapy in malignant tumors","volume":"8","author":"Meng","year":"2024","journal-title":"Precis Radiat Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:16:53Z","timestamp":1781849813000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15638","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}